Pep19

What It Is

Pep19 is a synthetic version of a small intracellular peptide that occurs naturally inside human cells. It is being studied as a metabolic-health compound that works through the endocannabinoid system — the signaling network that helps regulate appetite, fat storage and breakdown (lipolysis), energy use, and sleep. Unlike the cannabinoid drugs of the 2000s (such as rimonabant, a CB1 antagonist withdrawn over psychiatric side effects), Pep19 is reported to act peripherally rather than crossing into the central nervous system, which its developers argue may avoid the mood and anxiety effects that doomed earlier CB1-targeted weight drugs. In a triple-blind, placebo-controlled early-stage clinical trial published in 2026 in Diabetes/Metabolism Research and Reviews, 24 adults with obesity (BMI 30–35) took a once-daily oral capsule at bedtime for 60 days. The 5 mg dose produced about a 17% reduction in visceral fat — the metabolically dangerous fat around the organs that is strongly linked to cardiovascular disease and type 2 diabetes — along with reductions in body weight and waist circumference, and crucially no change in lean body mass. Both the 2 mg and 5 mg doses improved sleep quality, and no side effects were reported. Preclinical mouse work showed Pep19 also helps convert energy-storing white fat into calorie-burning brown fat and improves blood sugar, cholesterol, and blood pressure. The compound was developed by Proteimax Biotechnology with researchers at the University of São Paulo (ICB-USP) and the Pennington Biomedical Research Center. The data are early — a single small trial — and Pep19 is not approved by any regulator and is not a compounded or marketed product. It is also not on the FDA's July 2026 PCAC compounding review list.

Why Researchers Study It

Pep19 is interesting because it targets a different node than the dominant obesity drugs. GLP-1 and amylin therapies work largely through appetite suppression in the brain and can drive lean-mass loss alongside fat loss; ERR agonists and mitochondrial compounds target oxidative metabolism. Pep19 instead modulates the endocannabinoid system to act on fat storage and breakdown directly, and in its first human trial it preferentially reduced visceral fat while sparing lean mass and improving sleep — an unusual combination. It is also a test case for whether the endocannabinoid system, abandoned for weight loss after rimonabant's psychiatric side effects, can be re-approached safely with a peripherally acting peptide. The dual metabolic-plus-sleep signal is notable because poor sleep is itself a driver of obesity and metabolic dysfunction.

Proposed Mechanisms

• Acts on the endocannabinoid system to regulate appetite, lipolysis, and energy expenditure
• Reported to act peripherally rather than centrally, aiming to avoid CNS/psychiatric effects seen with CB1 antagonists
• Promotes browning of white adipose tissue (white-to-brown fat conversion) in preclinical models
• Preferentially reduces visceral adipose tissue while sparing lean body mass (early human data)
• Improves glycemic, lipid, and blood-pressure markers in preclinical models

Evidence Snapshot

Commonly Discussed Benefits

Safety & Cautions

Comparisons

See how Pep19 compares to related peptides:

Calculator Tools

Use our research tools to explore dosing and reconstitution data:

Citations

1. [1] Heimann A. et al. — Pep19: A Novel Approach for Reducing Visceral Fat and Improving Sleep Quality in Obese Adults — Results From an Early-Stage Clinical Trial. Diabetes/Metabolism Research and Reviews, 2026 PubMed
2. [2] Pep19 early-stage clinical trial — PMC full text PubMed
3. [3] Agência FAPESP — Study points out that a synthetic molecule helps reduce visceral fat and improve sleep (2025) PubMed

Related Peptides